David Robert Siemens
Queen's University
33 Papers
145 Citations
David Robert Siemens is an academic researcher from Queen's University. The author has contributed to research in topics: Bladder cancer & Population. The author has an hindex of 14, co-authored 33 publications.
Chat about Author
Papers
The Tumor Immune Contexture of Prostate Cancer.
TL;DR: It is surmised that the cumulative impact of factors such as the pre-treatment immune status, PTEN expression, DNA damage repair gene mutations, and the effects of conventionally used treatments on the anti-tumor immune response should be considered in immunotherapy trial design in PCa.
Augmenting Detection of Prostate Cancer in Transrectal Ultrasound Images Using SVM and RF Time Series
Mehdi Moradi,Parvin Mousavi,Alexander Boag,Eric Sauerbrei,David Robert Siemens,Purang Abolmaesumi +5 more
TL;DR: In this paper, the authors proposed a novel and accurate method based on ultrasound RF time series analysis and an extended version of support vector machine classification for generating probabilistic cancer maps that can augment ultrasound images of prostate and enhance the biopsy process.
94
Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study.
Christopher M. Booth,David Robert Siemens,Gavin Li,Yingwei Peng,Weidong Kong,David M. Berman,William J. Mackillop +6 more
TL;DR: Utilisation of cystectomy for bladder cancer in routine practice has increased over time with no evidence of a significant difference in CSS between radiotherapy and Cystectomy.
63
Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice
TL;DR: Most patients in the general population receive cisplatin, and this may be associated with superior outcomes to carboplatin, according to a retrospective cohort study on use of neoadjuvant and adjuvant chemotherapy in Ontario 1994-2008.
32
Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.
TL;DR: There may be an association between serum FSH levels and time to CRPC for men treated palliatively with ADT for advancing prostate cancer, and any clinical utility of FSH as a biomarker of progression or target for therapy is required.